Clinical Trials on Immunogenicity, Vaccine in Ireland

Total 15 results

Pfizer

Completed

A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.

Meningococcal Vaccine

United States, Finland, Czechia, Poland
IDeA States Pediatric Clinical Trials Network
National Institutes of Health (NIH); University of Nebraska; University of Montana

Active, not recruiting

Improving Pediatric COVID-19 Vaccine Uptake Using an mHealth Tool (MoVeUP)

Telemedicine | Pediatric ALL | Vaccine Hesitancy | COVID-19 Vaccines

United States
Vaxcyte, Inc.

Completed

Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults

Pneumococcal Vaccines

United States
Vaxcyte, Inc.

Completed

Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults

Pneumococcal Vaccines

United States
Pfizer

Completed

A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17

Vaccines | Meningococcal Vaccines

United States
Pfizer

Completed

A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age

Vaccines | Meningococcal Vaccines

United States
Vaxcyte, Inc.

Active, not recruiting

Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults

Pneumococcal Vaccines

United States
FluGen Inc
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old

Influenza Vaccine

United States
Bavarian Nordic

Completed

A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects

Smallpox

United States
GlaxoSmithKline

Completed

Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age

Infections, Papillomavirus | Papillomavirus Vaccines

United States
VBI Vaccines Inc.

Completed

Lot-to-lot Consistency of Sci-B-Vac™ in Adults

Hepatitis B Vaccines

United States, United Kingdom, Finland, Belgium, Canada, Germany
VBI Vaccines Inc.

Completed

Immunogenicity and Safety of Sci-B-Vac® to Engerix-B® in Adults

Hepatitis B Vaccines

United States, Canada, Finland, Belgium
GlaxoSmithKline

Completed

Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older

Herpes Zoster | Herpes Zoster Vaccine

United States, Australia, Spain, Finland, Germany, Japan, Taiwan, Canada, Sweden, Korea, Republic of, Czechia, Hong Kong, Mexico, Italy, Brazil, Estonia, France, United Kingdom
GlaxoSmithKline

Completed

Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.

Tetanus | Diphtheria | Acellular Pertussis | Diphtheria-Tetanus-acellular Pertussis Vaccines

United States
SillaJen, Inc.

Completed

Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone (PHOCUS)

Hepatocellular Carcinoma (HCC)

United States, Canada, New Zealand, Australia, China, France, Germany, Hong Kong, Israel, Italy, Korea, Republic of, Portugal, Singapore, Taiwan, Thailand, United Kingdom

3

Subscribe